Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: GlobeNewswire
NDA filing for Breakthrough Therapy designated AXS-05 in MDD expected in 4Q 2020 NDA filing for AXS-07 in migraine expected in 4Q 2020 Topline results for STRIDE-1 Phase 3 trial of AXS-05 in TRD on track for 1Q 2020 Topline results for INTERCEPT Phase 3 trial of AXS-07 in treatment of migraine on track for 1Q 2020 Topline results for ADVANCE Phase 2/3 trial of AXS-05 in Alzheimer’s disease agitation anticipated in 3Q 2020 Initiation of Phase 3 trial of AXS-12 in narcolepsy anticipated in 2020 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 12, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2019. “Axsome delivered on several transformative achievements in 2019, including positive NDA-enabling clinical trial readouts for
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $112.00 to $116.00. They now have an "outperform" rating on the stock.MarketBeat
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 11/12/24 - Beat
AXSM
Sec Filings
- 11/20/24 - Form 4
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- AXSM's page on the SEC website